Hypomethylating agent therapy use and survival in older patients with chronic myelomonocytic leukemia in the United States: A large population-based study.

about

TRIM proteins in blood cancers.A phase II trial of ruxolitinib in combination with azacytidine in myelodysplastic syndrome/myeloproliferative neoplasms.

P2860

Q47433060-529DDA10-CF5F-4D9C-865D-6B66A80255CE Q48309941-053A2FB6-6033-4D47-996C-11F16767F9EE

P2860

Hypomethylating agent therapy use and survival in older patients with chronic myelomonocytic leukemia in the United States: A large population-based study.

Item

http://www.wikidata.org/entity/Q40157327

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Hypomethylating agent therapy ...... large population-based study.

@en

type

Item

label

Hypomethylating agent therapy ...... large population-based study.

@en

prefLabel

Hypomethylating agent therapy ...... large population-based study.

@en

P1476

Hypomethylating agent therapy ...... A large population-based study

@en

P2093

Amer M Zeidan

http://www.w3.org/2001/XMLSchema#string

Jessica B Long

http://www.w3.org/2001/XMLSchema#string

Nikolai A Podoltsev

http://www.w3.org/2001/XMLSchema#string

Rong Wang

http://www.w3.org/2001/XMLSchema#string

Steven D Gore

http://www.w3.org/2001/XMLSchema#string

Xiaomei Ma

http://www.w3.org/2001/XMLSchema#string

P2860

The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

Comorbidity measures for use with administrative data.

Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B.

Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia.

Activity of decitabine, a hypomethylating agent, in chronic myelomonocytic leukemia.

Validation of disability status, a claims-based measure of functional status for cancer treatment and outcomes studies

An international data set for CMML validates prognostic scoring systems and demonstrates a need for novel prognostication strategies.

Treatment and outcomes for chronic myelomonocytic leukemia compared to myelodysplastic syndromes in older adults.

P304

3754-3762

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/CNCR.30814

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

123

http://www.w3.org/2001/XMLSchema#string

P50

Amy J Davidoff

Xin Hu

Scott F Huntington

P577

2017-06-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28621841

http://www.w3.org/2001/XMLSchema#string

P932

6540984

http://www.w3.org/2001/XMLSchema#string

Hypomethylating agent therapy use and survival in older patients with chronic myelomonocytic leukemia in the United States: A large population-based study.

about

P2860

P2860

Hypomethylating agent therapy use and survival in older patients with chronic myelomonocytic leukemia in the United States: A large population-based study.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P932